Organic compounds -- part of the class 532-570 series inventions 04/08

20080097085 - Crystalline maltitol powder less prone to consolidation and method for production thereof: The crystalline maltitol powder less prone to consolidation is obtained by charging crystalline or powdery maltitol into a shelf type dryer, a tunnel-type dryer, a cylindrical container, or the like and subjecting the equipment or container to a treatment wherein an air having a temperature of 30 to 33° C.... Agent: King & Spalding

20080097086 - Process for preparing anti-tumor oligosaccharide material from chitosan: The present invention relates to a process for preparing chito-oligosaccharide material by the enzymatic hydrolysis of chitinous materials, such as chitin, chitosan, and squid pen. The results of cell experiment showed that the oligosaccharide material of the invention causes a decrease in survival rate of U937 cell (a human leukemia... Agent: Bacon & Thomas, PLLC

20080097088 - Expression elements: The invention relates to genetic elements capable of improving the levels of expression of operably-linked transcription units. In particular, said genetic elements are derived from the 5′ untranslated regions of ribosomal protein genes and may comprise a CpG island. Also provided are vectors and host cells comprising said genetic elements... Agent: Cozen O'connor, P.C.

20080097087 - Peg-functional nucleic acid conjugate: The invention provides a conjugate of functional oligonucleotide with poly(ethylene oxide), polyion complex of the conjugate with cationic polymer, and micelle thereof. The micelle improves stability of the oligonucleotide in animal cells and its specific bindability to target gene.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080097089 - Sirna targeting deubiqutination enzymes: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080097090 - Functional and hyperfunctional sirna directed against bcl-2: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.... Agent: Kalow & Springut LLP

20080097092 - Sirna targeting kinases: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080097091 - Sirna targeting tnfalpha: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080090998 - Genes and uses for plant improvement: Transgenic seed for crops with improved traits are provided by trait-improving recombinant DNA where plants grown from such transgenic seed exhibit one or more improved traits as compared to a control plant. Exemplary recombinant DNA expresses a succinate semialdehyde dehydrogenase.... Agent: Monsanto Company

20080090999 - Nucleotide and amino acid sequences from xenorhabdus and uses thereof: The invention provides isolated nucleotide sequences from Xenorhabdus nematophila species Xs86068, and, in particular, nucleotide sequences that encode insect inhibitory proteins, the insecticidal proteins, and compositions that comprise one or more of the insecticidal proteins for use in controlling insect infestation.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080090997 - Sirna targeting complement component 3 (c3): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080091000 - Stress-inducible plant promoters: The present invention discloses and claims stress-inducible plant promoters, DNA constructs with such promoters, transgenic plants containing such promoters and DNA constructs, isolated DNAs encoding such promoters, and methods of making and using such promoters, DNA constructs, transgenic plants, and isolated DNAs.... Agent: Sonnenschein Nath & Rosenthal LLP

20080091001 - Functional and hyperfunctional sirna directed against bcl-2: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.... Agent: Kalow & Springut LLP

20080091002 - Functional and hyperfunctional sirna directed against bcl-2: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.... Agent: Kalow & Springut LLP

20080091003 - Functional and hyperfunctional sirna directed against bcl-2: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.... Agent: Kalow & Springut LLP

20080091004 - Functional and hyperfunctional sirna directed against bcl-2: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.... Agent: Kalow & Springut LLP

20080091005 - Modified nucleotides, methods for making and using same: Modified nucleotides are disclosed for use in single molecule sequencing, methods for making the modified nucleotides and method for using the modified nucleotides. Linkers for making the modified nucleotide are also disclosed.... Agent: Robert W Strozier, P.l.l.c

20080091006 - Nitrate ester cyclodextrin complexes: The invention relates to 1:1 complexes of organic nitrate esters with cyclodextrins, to the production of these complexes and to the use thereof in the field of coronary medicine.... Agent: Fulbright & Jaworski, LLP

20080091007 - Modified cellulose films: A hydroxypropyl methyl cellulose film comprises hydroxypropyl methyl cellulose plasticised with a plasticiser comprising a fruit acid or a salt or a fruit acid, preferably lactic acid. The film is safe for human consumption and finds use as a wall material of an ingestible delivery capsule, e.g. containing a dose... Agent: Mcdermott, Will & Emery LLP

20080085996 - Use of phytoene synthase for controlling transgene escape: The present invention is related to a recoverable block of function (RBF) system for controlling transgene escape and transgene containment in plants. The RBF-system comprises at least one blocking construct (BC), wherein the BC comprises as the blocking gene a nucleotide sequence or crtB gene encoding phytoene synthase, which is... Agent: Dodds & Associates

20080085995 - Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor: Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations... Agent: Seed Intellectual Property Law Group Pllc

20080085997 - Sirna targeting phosphoinositide-3-kinase, class 2, beta polypeptide (pik3c2b): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080085998 - Sirna targeting transient receptor potential cation channel, subfamily v, member 1 (trpv1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080085999 - Modulation of gene expression using dna-rna hybrids: The present invention is directed to novel DNA-RNA hybrids comprising either a DNA sense strand and an RNA antisense strand, or an RNA sense strand and a DNA antisense strand. The compounds of the invention, and compositions and arrays comprising the same, may be used for a variety of purposes,... Agent: Seed Intellectual Property Law Group Pllc

20080086000 - Prostaglandin reductase: An isolated polypeptide containing the sequence of SEQ ID NO:1 or a functional equivalent of SEQ ID NO:1, in which the polypeptide reduces 15-keto prostaglandin but not leukotriene B4. Also disclosed is an antibody that binds specifically to the polypeptide and a double-stranded ribonucleic acid for inhibiting expression of the... Agent: Occhiuti Rohlicek & Tsao, LLP

20080086001 - Sirna targeting intercellular adhesion molecule 1 (icam1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080086002 - Sirna targeting secreted frizzled-related protein 1 (sfrp1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080081903 - Method for screening transcriptional coregulatory proteins of transcription factors, and androgen receptor transcriptional coregulatory proteins as targets for androgen receptor-dependent diseases: The present invention also provides a method for screening and isolating transcriptional coregulatory proteins of transcription factors. Using this method, a new class of proteins, androgen receptor transcriptional coregulatory proteins, that interact with the androgen receptor N-terminus to regulate transcriptional activation, which are targets for identifying and isolating inhibitors that... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080081904 - Sirna targeting carbonic anhydrase 4(ca4): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20080081905 - Preparation and uses of locked-ring sugar c-glycoside derivatives: “Locked-ring” C-glycoside derivatives may be prepared wherein the ring of the sugar molecule remains intact without the need for any protecting groups. These C-glycoside derivatives may be produced by first reacting an aldose reducing sugar, which may be a hexose or a pentose, with a β-diketone to form a C-glycoside... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research